Radiopharm Theranostics (ASX:RAD) said a phase 2b trial of RAD101 in participants with suspected recurrence of brain metastases after radiotherapy met its primary endpoint, according to a Wednesday filing with the Australian bourse.

The analysis of the imaging data for all assessed lesions showed 93% concordance between magnetic resonance imaging and PET scans of brain metastases, per the filing.

Meanwhile, 14 patients with evaluable six-month data showed preliminary sensitivity of 86%, a gauge of an imaging test's ability to correctly identify patients with disease.

The results also showed "substantial and selective tumor uptake of RAD101," supporting its progression into an intended registrational phase 3 program, the company said.